183 related articles for article (PubMed ID: 31994703)
1. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes.
Storey RF; Gurbel PA; Ten Berg J; Bernaud C; Dangas GD; Frenoux JM; Gorog DA; Hmissi A; Kunadian V; James SK; Tanguay JF; Tran H; Trenk D; Ufer M; Van der Harst P; Van't Hof AWJ; Angiolillo DJ
Eur Heart J; 2020 Sep; 41(33):3132-3140. PubMed ID: 31994703
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
Sinnaeve P; Fahrni G; Schelfaut D; Spirito A; Mueller C; Frenoux JM; Hmissi A; Bernaud C; Ufer M; Moccetti T; Atar S; Valgimigli M
J Am Coll Cardiol; 2020 May; 75(20):2588-2597. PubMed ID: 32439008
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y
Henrich A; Claussen CH; Dingemanse J; Krause A
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):735-747. PubMed ID: 33955698
[TBL] [Abstract][Full Text] [Related]
4. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Schilling U; Dingemanse J; Dobrow M; Baumann M; Riederer MA; Juif PE; Ufer M
Thromb Haemost; 2021 Jun; 121(6):755-766. PubMed ID: 33412611
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacology of the Reversible and Potent P2Y
Juif PE; Boehler M; Dobrow M; Ufer M; Dingemanse J
J Clin Pharmacol; 2019 Jan; 59(1):123-130. PubMed ID: 30088663
[TBL] [Abstract][Full Text] [Related]
6. Selatogrel, a novel P2Y
Milluzzo RP; Franchina GA; Capodanno D; Angiolillo DJ
Expert Opin Investig Drugs; 2020 Jun; 29(6):537-546. PubMed ID: 32396484
[TBL] [Abstract][Full Text] [Related]
7. The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration.
Baumann M; Lack B; Guillaumat I; Murphy MJ; Riederer MA
Platelets; 2022 Jan; 33(1):147-156. PubMed ID: 33427002
[TBL] [Abstract][Full Text] [Related]
8. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y
Zenklusen I; Hsin CH; Schilling U; Kankam M; Krause A; Ufer M; Dingemanse J
Clin Pharmacokinet; 2022 May; 61(5):687-695. PubMed ID: 34961905
[TBL] [Abstract][Full Text] [Related]
9. Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects.
Ufer M; Huynh C; van Lier JJ; Caroff E; Fischer H; Dingemanse J
Xenobiotica; 2020 Apr; 50(4):427-434. PubMed ID: 31322041
[TBL] [Abstract][Full Text] [Related]
10. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
[TBL] [Abstract][Full Text] [Related]
11. Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists.
Hsin CH; Dingemanse J; Henrich A; Bernaud C; Gehin M; Krause A
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759765
[No Abstract] [Full Text] [Related]
12. Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model.
Crescence L; Darbousset R; Caroff E; Hubler F; Riederer MA; Panicot-Dubois L; Dubois C
Thromb Res; 2021 Apr; 200():133-140. PubMed ID: 33610885
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
14. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction.
Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S
J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction.
Gehin M; Storey RF; Bernaud C; Dingemanse J
Expert Opin Drug Metab Toxicol; 2023; 19(10):697-708. PubMed ID: 37795868
[TBL] [Abstract][Full Text] [Related]
16. Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
Beavers CJ; Effoe SA; Dobesh PP
J Cardiovasc Pharmacol; 2022 Feb; 79(2):161-167. PubMed ID: 34132688
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y
Parker WAE; Storey RF
Expert Opin Emerg Drugs; 2020 Mar; 25(1):1-6. PubMed ID: 32064955
[No Abstract] [Full Text] [Related]
18. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
19. A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial.
Baldoni D; Bruderer S; Krause A; Gutierrez M; Gueret P; Astruc B; Dingemanse J
Clin Drug Investig; 2014 Nov; 34(11):807-18. PubMed ID: 25331625
[TBL] [Abstract][Full Text] [Related]
20. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel.
Schilling U; Hsin CH; Delahaye S; Krause A; Wuelfrath H; Halabi A; Dingemanse J
Clin Transl Sci; 2022 Aug; 15(8):1906-1915. PubMed ID: 35583936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
